#1 Clinical Trials Search in Europe

Clostridia, Cluster Xiva, Strain Relative Sellimonas Intestinalis, Live

This article examines recent clinical trials investigating the use of live bacterial strains, particularly Clostridia species, for treating intestinal conditions like Clostridioides difficile infection (CDI) and ulcerative colitis. These trials aim to evaluate the safety and efficacy of novel microbial-based therapies that may help restore balance to the gut microbiome and improve patient outcomes.

Table of Contents

What is CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE SELLIMONAS INTESTINALIS, LIVE?

CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE SELLIMONAS INTESTINALIS, LIVE is a type of live bacterial strain that is being studied as a potential treatment for certain gut-related conditions. It is part of a larger group of bacterial strains that make up investigational drugs called VE303 and VE202.[1][2]

This bacterial strain, along with others, is being developed as a live biotherapeutic product (LBP). LBPs are a new class of drugs that contain live organisms, such as bacteria, that are used to prevent, treat, or cure a disease or condition in humans.

What conditions does it treat?

Based on the clinical trials information provided, this bacterial strain is being investigated for the treatment of two main conditions:

  1. Clostridioides difficile infection (CDI): This is a serious intestinal infection that can cause severe diarrhea and potentially life-threatening inflammation of the colon. The drug VE303, which contains this bacterial strain, is being studied for preventing recurrent CDI.[1]
  2. Ulcerative colitis (UC): This is a type of inflammatory bowel disease that causes inflammation and ulcers in the digestive tract. The drug VE202, which also contains this bacterial strain, is being investigated for treating mild-to-moderate UC.[2]

How does it work?

While the exact mechanism of action is not fully described in the provided information, we can infer that this bacterial strain, along with others in the VE303 and VE202 formulations, likely works by modulating the gut microbiome. The gut microbiome is the community of microorganisms living in our digestive tract that plays a crucial role in our health.

In the case of CDI, these beneficial bacteria may help prevent the overgrowth of harmful C. difficile bacteria by:

  • Competing for resources in the gut
  • Producing substances that inhibit C. difficile growth
  • Strengthening the gut’s natural defenses

For ulcerative colitis, the bacterial strains may help reduce inflammation and promote healing of the gut lining by:

  • Modulating the immune response
  • Producing beneficial metabolites
  • Improving the gut barrier function

Current clinical trials

Two major clinical trials are currently underway to investigate the effectiveness and safety of products containing this bacterial strain:

1. VE303 for Clostridioides difficile infection (CDI)

This is a Phase 3 study called the RestoratiVE303 Study. It aims to evaluate VE303 for preventing recurrent CDI. Key points include:[1]

  • It’s a randomized, double-blind, placebo-controlled study
  • Participants receive either VE303 or a placebo for 14 days
  • The main goal is to compare CDI recurrence rates at 8 weeks between VE303 and placebo groups
  • The study also looks at safety, quality of life, and how well the bacterial strains colonize the gut

2. VE202 for Ulcerative Colitis (UC)

This is a Phase 2 study investigating VE202 for mild-to-moderate ulcerative colitis. Important aspects include:[2]

  • It’s also a randomized, double-blind, placebo-controlled study
  • Participants receive VE202 or placebo for 8 weeks
  • The main goal is to evaluate the endoscopic response (improvement in the appearance of the colon lining) after 8 weeks of treatment
  • The study also assesses safety and tolerability of VE202

How is it administered?

Both VE303 and VE202 are administered orally as capsules. In the clinical trials:[1][2]

  • VE303 is given daily for 14 consecutive days
  • VE202 is given for 8 weeks

The exact dosing regimen may vary depending on the specific trial and treatment phase.

Potential side effects

As these are investigational drugs, the full range of potential side effects is not yet known. The clinical trials are designed to assess the safety and tolerability of these treatments. Some general considerations for live bacterial treatments may include:

  • Gastrointestinal symptoms (e.g., bloating, gas, diarrhea)
  • Potential risk of infection in immunocompromised individuals
  • Allergic reactions

It’s important to note that the clinical trials have specific safety monitoring protocols in place to identify and manage any adverse events that may occur.

Ongoing research and future directions

The development of live bacterial treatments like VE303 and VE202 represents an exciting new frontier in medicine. These therapies aim to harness the power of beneficial bacteria to treat complex gut-related conditions.

Future research may explore:

  • The use of these bacterial strains for other gastrointestinal disorders
  • Optimizing the combination and dosing of bacterial strains for maximum effectiveness
  • Long-term safety and efficacy of these treatments
  • Potential interactions with other medications or treatments

As clinical trials progress, we’ll gain more insight into the potential of CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE SELLIMONAS INTESTINALIS, LIVE and related bacterial strains in treating CDI, UC, and possibly other conditions.

Aspect VE303 Trial (CDI) VE202 Trial (Ulcerative Colitis)
Condition Clostridioides difficile infection Mild-to-moderate ulcerative colitis
Drug VE303 (live bacterial strains) VE202 (live bacterial strains)
Administration Oral capsules for 14 days Oral capsules for 8 weeks
Primary Endpoint CDI recurrence rate at Week 8 Endoscopic response rate at Day 56
Key Inclusion Criteria Age ≥12 years, confirmed CDI episode Age 18-75, active mild to moderate UC
Key Exclusion Criteria Chronic diarrhea, other infectious diarrhea Crohn’s disease, active infection
Safety Assessments Adverse events, serious adverse events Grade ≥3 treatment-related adverse events

FAQ

  • What conditions are being targeted in these clinical trials? The clinical trials are targeting Clostridioides difficile infection (CDI) and mild-to-moderate ulcerative colitis.
  • What is the main drug being studied in these trials? The main drugs being studied are VE303 and VE202, which contain live bacterial strains, particularly various Clostridia species.
  • How are these drugs administered? Both VE303 and VE202 are administered orally in capsule form.
  • What are the primary goals of these clinical trials? The primary goals are to evaluate the efficacy of the drugs in preventing CDI recurrence or improving ulcerative colitis symptoms, as well as to assess their safety profiles.
  • How long do the treatment periods last in these trials? The treatment periods vary, with VE303 being administered for 14 days in the CDI trial, and VE202 being given for 8 weeks in the ulcerative colitis trial.

Ongoing Clinical Trials on Clostridia, Cluster Xiva, Strain Relative Sellimonas Intestinalis, Live

  • Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +8

  • Study on VE202 for Patients with Mild-to-Moderate Ulcerative Colitis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Hungary Lithuania The Netherlands Poland

Glossary

  • Clostridioides difficile infection (CDI): A bacterial infection that can cause diarrhea and serious intestinal conditions like colitis. It often occurs after using antibiotics.
  • Ulcerative colitis: A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract, primarily affecting the colon and rectum.
  • Microbiome: The collection of all microorganisms, such as bacteria, fungi, and viruses, that naturally live on and in our bodies.
  • Probiotic: Live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.
  • Endoscopic response: An improvement in the appearance of the intestinal lining as observed through an endoscope, which is a tool used to visually examine the inside of the body.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Randomized controlled trial: A type of scientific experiment where participants are randomly allocated to receive either the treatment being tested or a placebo/standard treatment, allowing for comparison of outcomes.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Efficacy: The ability of a drug or medical treatment to produce the desired beneficial effect.
  • Recurrence: The return of a disease or symptoms after a period of improvement or remission.

References

  1. http://clinicaltrials.eu/trial/study-on-ve303-for-preventing-recurrent-c-difficile-infection-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-ve202-for-patients-with-mild-to-moderate-ulcerative-colitis/